Recurrent Non-small Cell Lung Cancer and Stage IV Non-small Cell Lung Cancer Clinical Trial Using cabozantinib-s-malate, erlotinib hydrochloride and laboratory biomarker analysis

- The folks at National Cancer Institute (NCI) are studying the effects of cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis on Recurrent Non-small Cell Lung Cancer and Stage IV Non-small Cell Lung Cancer in individuals ages 18 years and older. This clinical trial is slated to start May 2013.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy."

Locations

University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania - Recruiting

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania - Recruiting

Wayne State University-Karmanos Cancer Institute

Detroit, Michigan - Recruiting

City of Hope- South Pasadena Cancer Center

South Pasadena, California - Recruiting

UC Davis Comprehensive Cancer Center

Sacramento, California - Recruiting

University of Southern California

Los Angeles, California - Recruiting

City of Hope

Duarte, California - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.